SCHEMBL30311024

SCHEMBL30311024

CC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ACE P12821 3/20 0.70
ALOX15 P16050 1/20 0.68
ECE1 P42892 9/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetyltryptophan SCHEMBL29360698 0.92 ALOX15 (0.79) ACEALOX15ECE1
Acetyltryptophan SCHEMBL57141 0.92 ALOX15 (0.79) ACEALOX15ECE1
Acetyltryptophan SCHEMBL29401158 0.92 ALOX15 (0.79) ACEALOX15ECE1
Acetyltryptophan SCHEMBL702442 0.92 ALOX15 (0.79) ACEALOX15ECE1
Acetyltryptophan SCHEMBL4216450 0.92 ALOX15 (0.79) ACEALOX15ECE1
Acetyltryptophan SCHEMBL4216452 0.92 ALOX15 (0.79) ACEALOX15ECE1
Acetyltryptophan SCHEMBL57140 0.92 ALOX15 (0.79) ACEALOX15ECE1
SCHEMBL30310774 0.91 ACE (0.67) ACEALOX15ECE1
Acetyltryptophan SCHEMBL23933298 0.91 ALOX15 (0.77) ACEALOX15ECE1
Acetyltryptophan SCHEMBL1427071 0.91 ALOX15 (0.77) ACEALOX15ECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-09-25 US claimed
CN-118632858-A Gastric inhibitory peptide receptor ligands 3B制药有限公司 2024-09-10 CN claimed
EP-4423110-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-09-04 EP claimed
WO-2023072971-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-05-04 WO claimed
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-09-25 US disclosed
CN-118632858-A Gastric inhibitory peptide receptor ligands 3B制药有限公司 2024-09-10 CN disclosed
EP-4423110-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-09-04 EP disclosed
CN-118515597-A Visible light mediated tryptophan indole C-2 site selective arylation modification method and application thereof 中国科学院深圳先进技术研究院 2024-08-20 CN disclosed
WO-2023072971-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-05-04 WO disclosed
EP-4170347-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2023-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS GIPR, VIP, GRPR ACE 3951/4885ALOX15 1681/4885ECE1 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.